Raloxifene

Overview

Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.[1] WP

Common side effects include hot flashes, leg cramps, swelling, and joint pain. Severe side effects may include blood clots and stroke. Use during pregnancy may harm the baby. The medication may worsen menstrual symptoms. Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus.[1][2] WP

Raloxifene was approved for medical use in the United States in 1997. It is available as a generic medication. In 2020, it was the 292nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[1][3][4][5] WP

Drug class

Selective estrogen receptor modulator WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Raloxifene is used for the treatment and prevention of osteoporosis in postmenopausal women. It is used at a dosage of 60 mg/day for both the prevention and treatment of osteoporosis. In the case of either osteoporosis prevention or treatment, supplemental calcium and vitamin D should be added to the diet if daily intake is inadequate.[6][7][8] WP

Raloxifene is used to reduce the risk of breast cancer in postmenopausal women. It is used at a dosage of 60 mg/day for this indication. In the Multiple Outcomes of Raloxifene (MORE) clinical trial, raloxifene decreased the risk of all types of breast cancer by 62%, of invasive breast cancer by 72%, and of invasive estrogen receptor-positive breast cancer by 84%. Conversely, it does not reduce the risk of estrogen receptor-negative breast cancer. There were no obvious differences in effectiveness of raloxifene in the MORE trial for prevention of breast cancer at a dosage of 60 mg/m²/day relative to 120 mg/m²/day. In the Study of Tamoxifen and Raloxifene (STAR) trial, 60 mg/day raloxifene was 78% as effective as 20 mg/day tamoxifen in preventing non-invasive breast cancer. Women with undetectable levels of estradiol (<2.7 pg/mL) have a naturally low risk of breast cancer and, in contrast to women with detectable levels of estradiol, do not experience significant benefit from raloxifene in terms of reduction of breast cancer risk.[7][9][10] WP

Clinical effects

Raloxifene has antiestrogenic effects in the mammary glands in preclinical studies. In accordance, raloxifene reduces breast density in postmenopausal women, a known risk factor for breast cancer. It does not stimulate the uterus in postmenopausal women, and results in no increase in risk of endometrial thickening, vaginal bleeding, endometrial hyperplasia, or endometrial cancer. At the same time, raloxifene has minimal antiestrogenic effect in the uterus in premenopausal women. This may possibly be due to inadequate tissue exposure of the uterus to raloxifene in these estrogen-rich individuals.[11–14] WP

In premenopausal women, raloxifene increases levels of follicle-stimulating hormone (FSH) and estradiol. Conversely, in postmenopausal women, raloxifene has been found to reduce levels of the gonadotropins, luteinizing hormone (LH) and FSH, while not affecting levels of estradiol. Raloxifene also decreases prolactin levels in postmenopausal women. In men, raloxifene has been found to disinhibit the hypothalamic–pituitary–gonadal axis (HPG axis) and thereby increase total testosterone levels. Due to the simultaneous increase in sex hormone-binding globulin (SHBG) levels however, free testosterone levels often remain unchanged in men during therapy with raloxifene.[9][13][15–18] WP

Raloxifene has estrogenic effects on liver protein synthesis. It increases SHBG levels in both pre- and postmenopausal women as well as in men. The medication decreases levels of total and low-density lipoprotein (LDL) cholesterol, C-reactive protein, apolipoprotein B, and homocysteine. Conversely, it has little effect on levels of triglycerides and high-density lipoprotein (HDL). Raloxifene has been shown to inhibit the oxidation of LDL cholesterol in vitro. The medication has been found to decrease insulin-like growth factor 1 (IGF-1) levels in pre- and postmenopausal women as well as in men. It has also been found to increase insulin-like growth factor binding protein 3 (IGFBP-3) levels in pre- and postmenopausal women. Due to activation of estrogen receptors in the liver, raloxifene has procoagulatory effects, such as decreasing levels of fibrinogen and influencing levels of other coagulation factors. For these reasons, raloxifene increases the risk of thrombosis.[9][11][13][15][16] WP

Raloxifene increases bone mineral density in postmenopausal women but decreases it in premenopausal women. In the MORE trial, the risk of vertebral fractures was decreased by 30%, and bone mineral density was increased in the spine (by 2.1% at 60 mg, 2.4% at 120 mg) and femoral neck (2.6% at 60 mg, 2.7% at 120 mg). It has been found to possess estrogenic effects in adipose tissue in postmenopausal women, promoting a shift from an android fat distribution to a gynoid fat distribution. The medication has been found to increase levels of leptin, an adipokine.[9][19][20][21] WP

Risks and side effects

Contraindications

Raloxifene is contraindicated in lactating women or women who are or who may become pregnant. It also may be of concern to women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.[22][23] WP

Side effects

Common side effects of raloxifene include hot flashes (25–28% vs. 18–21% for placebo), vaginal dryness, and leg cramps (generally mild; 5.5% vs. 1.9% for placebo). Raloxifene does not cause breast tenderness, endometrial hyperplasia, menstrual bleeding, or endometrial cancer. It does not appear to affect cognition or memory. Raloxifene is a teratogen; i.e., it can cause developmental abnormalities such as birth defects.[9][11][22–25] WP⚠ Wikipedia itself has flagged this text: citation needed.

Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, and vision changes. Black box warnings were added to the label of raloxifene in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risk for deep vein thrombosis and pulmonary embolism. The risk of venous thromboembolism with raloxifene is increased by several-fold in postmenopausal women (RR (relative risk) = 3.1). Raloxifene has a lower risk of thromboembolism than tamoxifen. In the MORE trial, raloxifene caused a 40% decrease in risk of cardiovascular events in women who were at increased risk for coronary artery disease, although there was no decrease in cardiovascular events for the group as a whole.[9][10][19][22][24] WP

A report in September 2009, from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen and raloxifene used to treat breast cancer, significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.[26] WP

A human case report in July 2016, suggests that raloxifene may in fact, at some point, also stimulate breast cancer growth leading to a reduction of advanced breast cancer disease upon the withdrawal of the drug.[27] WP

Unlike other SERMs, such as tamoxifen, raloxifene has no risk of uterine hyperplasia or endometrial cancer (RR (relative risk) = 0.8).[10][19][24] WP

Raloxifene does not increase the incidence of breast pain or tenderness in postmenopausal women.[11][14] WP

Overdose

Raloxifene has been studied in clinical trials across a dosage range of 30 to 600 mg/day, and was well-tolerated at all dosages.[11] WP

Pharmacology

Mechanism of action

Raloxifene is a selective estrogen receptor modulator (SERM) and hence is a mixed agonist and antagonist of the estrogen receptor (ER) in different tissues. It has estrogenic activity in some tissues, such as bone and the liver, and antiestrogenic activity in other tissues, such as the breasts and uterus. Its affinity (Kd) for the ERα is approximately 50 pM, which is similar to that of estradiol. Relative to estradiol, raloxifene has been reported to possess about 8 to 34% of the affinity for the ERα and 0.5 to 76% of the affinity for the ERβ. Raloxifene acts as a partial agonist of the ERα and as a pure antagonist of the ERβ. In contrast to the classical ERs, raloxifene is an agonist of the G protein-coupled estrogen receptor (GPER) (EC₅₀ (half-maximal effective concentration) = 10–100 nM), a membrane estrogen receptor.[1][11][28–33] WP

Absorption

The absorption of raloxifene is approximately 60%. However, due to extensive first-pass metabolism, the absolute bioavailability of raloxifene is only 2.0%. Raloxifene is rapidly absorbed from the intestines upon oral administration. Peak plasma levels of raloxifene occur 0.5 to 6 hours after an oral dose. In healthy postmenopausal women treated with 60 mg/day raloxifene, peak circulating raloxifene levels normalized by dose and body weight were (i.e., divided by (mg/kg)), 0.50 ng/mL (500 pg/mL) after a single dose and 1.36 ng/mL (1,360 pg/mL after multiple doses).[22][24][34] WP

Distribution

Raloxifene is widely distributed throughout the body. There is extensive distribution of raloxifene into the liver, serum, lungs, and kidneys. The volume of distribution of raloxifene with a single 30 to 150 mg oral dose is approximately 2348 L/kg, which corresponds to ~170,000 L for a 72 kg person. Both raloxifene and its glucuronide metabolites show high plasma protein binding (>95%), including to both albumin and α₁ acid glycoprotein, but not to sex hormone-binding globulin. More specifically, raloxifene is 98.2 ± 0.4% bound to plasma proteins.[24][34][35][36] WP

Metabolism

Raloxifene is metabolized in the liver and undergoes enterohepatic recycling. It is metabolized exclusively by glucuronidation and is not metabolized by the cytochrome P450 system. Less than 1% of radiolabeled material in plasma comprises unconjugated raloxifene. The metabolites of raloxifene include several glucuronides. The elimination half-life of raloxifene after a single dose is 27.7 hours (1.2 days), whereas its half-life at steady state at a dosage of 60 mg/day is 15.8 to 86.6 hours (0.7–3.6 days), with an average of 32.5 hours (1.4 days). The extended half-life of raloxifene is attributed to enterohepatic recirculation and its high plasma protein binding. Raloxifene and its glucuronide conjugates are interconverted by reversible metabolism and enterohepatic recycling, which prolongs the elimination half-life of raloxifene with oral administration. The medication is deconjugated into its active form in a variety of tissues, including liver, lungs, spleen, bone, uterus, and kidneys.[22][24][34] WP

Elimination

Raloxifene is mainly excreted in bile and is eliminated in feces. Less than 0.2% of a dose is excreted unchanged in urine and less than 6% of a dose is excreted in urine as glucuronide conjugates.[24][34] WP

Research

Research

Clinical studies of raloxifene for metastatic breast cancer in women have been conducted but found little effectiveness at 60 mg/day in those previously treated with tamoxifen, though modest effectiveness has been observed at higher doses. In contrast to tamoxifen, raloxifene is not approved for the treatment of breast cancer.[9][37][38] WP

Raloxifene has been studied in men for a variety of uses, such as for treatment of schizophrenia, prostate cancer, and osteoporosis. It has been studied in combination with castration and bicalutamide, a nonsteroidal antiandrogen, for the treatment of prostate cancer.[17][18][39–47] WP

Raloxifene has been studied as an adjunct in the treatment of schizophrenia in postmenopausal women. A 2017 meta-analysis concluded that it was safe and effective for this indication, although further studies with larger sample sizes are needed for confirmation. It may be effective in women with less severe symptoms.[48] WP

A tissue-selective estrogen-receptor complex (TSEC) of estradiol and raloxifene has been studied in postmenopausal women.[49] WP

Raloxifene (60 mg/day) was reported to be effective in the treatment of pubertal gynecomastia in adolescent boys in a small retrospective chart review. Other SERMs are also known to be effective in the treatment of gynecomastia.[50–53] WP

Raloxifene has been reported to augment the antidepressant effects of selective serotonin reuptake inhibitors (SSRIs).[54] WP

History

History

Raloxifene was approved in the United States for the prevention of postmenopausal osteoporosis in 1997, the treatment of postmenopausal osteoporosis in 1999, and to prevent or reduce the risk of breast cancer in certain postmenopausal women in 2007. It received orphan designation in 2005.[55–58] WP

Legal status

Names

Raloxifene is the generic name of the drug and its INN (International Nonproprietary Name) and BAN (British Approved Name), while raloxifène is its DCF (Dénomination Commune Française) and raloxifene hydrochloride is its USAN (United States Adopted Name), BANM (British Approved Name), and JAN (Japanese Accepted Name). It has also been known by the name keoxifene.[59–62] WP

Raloxifene is sold mainly under the brand name Evista and to a lesser extent the brand name Optruma. It is also sold under a variety of other brand names in various countries.[60][62] WP

Availability

Raloxifene is available widely throughout the world, including in the United States, Canada, the United Kingdom, Ireland, elsewhere throughout Europe, Australia, New Zealand, South Africa, Latin America, Southern, Eastern, and Southeastern Asia, and elsewhere in the world such as in Israel and Egypt.[60][62] WP

Raloxifene is provided in the form of 60 mg oral tablets.[7] WP

Controversy

An editorial in Lancet Oncology criticized the way that research about the medication for breast cancer prevention was released.[63] WP

Chemistry

Formula

C28H27NO4S PC

CAS number

84449-90-1 PC

Molar mass (g/mol)

473.6 PC

IUPAC name (computed by PubChem)

[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone PC

SMILES

C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O PC

InChIKey

GZUITABIAKMVPG-UHFFFAOYSA-N PC

PubChem CID

5035

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Raloxifene Hydrochloride Monograph for Professionals
2. Journal / agency Yang ZD, Yu J, Zhang Q. Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: a systematic review of randomized controlled trials. Maturitas. August 2013. doi:10.1016/j.maturitas.2013.05.010 · PMID 23764354
3. Other British national formulary: BNF 76. 2018
4. Other The Top 300 of 2020
5. Other Raloxifene - Drug Usage Statistics
6. Journal / agency Raloxifene: MedlinePlus Drug Information
7. Other Mosby. Mosby's Drug Reference for Health Professions - E-Book. 5 March 2013
8. Journal / agency Ohta H, Hamaya E, Taketsuna M, Sowa H. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study. Current Medical Research and Opinion. January 2015. doi:10.1185/03007995.2014.975339 · PMID 25299349
9. Journal / agency Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. Journal of Clinical Oncology. March 2005. doi:10.1200/JCO.2005.11.005 · PMID 15755972
10. Other Bland KI, Copeland EM, Klimberg VS, Gradishar WJ. The Breast E-Book: Comprehensive Management of Benign and Malignant Diseases. 29 June 2017
11. Journal / agency Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. A pharmacological review of selective oestrogen receptor modulators. Human Reproduction Update. 2000. doi:10.1093/humupd/6.3.212 · PMID 10874566
12. Journal / agency Jeon-Hor, Chen. Reduction of Breast Density Following Tamoxifen Treatment Evaluated by 3-D MRI: Preliminary Study. Magn Reson Imaging. September 15, 2003. doi:10.1016/j.mri.2010.07.009 · PMID 20832226 · PMC3005955
13. Journal / agency Draper MW, Chin WW. Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators. Clinical Obstetrics and Gynecology. June 2003. doi:10.1097/00003081-200306000-00008 · PMID 12808380
14. Journal / agency Haskell SG. Selective estrogen receptor modulators. Southern Medical Journal. May 2003. doi:10.1097/01.SMJ.0000051146.93190.4A · PMID 12911186
15. Journal / agency Corona G, Rastrelli G, Ratrelli G, Maggi M. The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother. February 2015. doi:10.1517/14656566.2015.993607 · PMID 25523084
16. Journal / agency Duarte FH, Jallad RS, Bronstein MD. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine. November 2016. doi:10.1007/s12020-016-1118-z · PMID 27704479
17. Journal / agency Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. April 2012. doi:10.1210/jc.2011-3347 · PMID 22319035
18. Journal / agency Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J. Bone Miner. Res. September 2004. doi:10.1359/JBMR.040503 · PMID 15312253
19. Journal / agency Park WC, Jordan VC. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends in Molecular Medicine. February 2002. doi:10.1016/S1471-4914(02)02282-7 · PMID 11815274
20. Journal / agency Xu B, Lovre D, Mauvais-Jarvis F. Effect of selective estrogen receptor modulators on metabolic homeostasis. Biochimie. May 2016. doi:10.1016/j.biochi.2015.06.018 · PMID 26133657
21. Journal / agency Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. Journal of Endocrinological Investigation. 2014. doi:10.1007/BF03347261 · PMID 16218045
22. Journal / agency Raloxifene label Last updated 09/2007]
23. Journal / agency Gizzo S, Saccardi C, Patrelli TS, Berretta R, Capobianco G, Di Gangi S, Vacilotto A, Bertocco A, Noventa M, Ancona E, D'Antona D, Nardelli GB. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013. doi:10.1097/OGX.0b013e31828baef9 · PMID 23942473
24. Journal / agency Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clinical Pharmacokinetics. 2003. doi:10.2165/00003088-200342040-00004 · PMID 12648026
25. Journal / agency Seeman E. Raloxifene. J. Bone Miner. Metab. 2001. doi:10.1007/s007740170043 · PMID 11281162
26. Other Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects. September 2009
27. Journal / agency Lemmo W. Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report. Integrative Cancer Therapies. September 2016. doi:10.1177/1534735416658954 · PMID 27411856 · PMC5739193
28. Journal / agency Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chemistry & Biology. May 2001. doi:10.1016/S1074-5521(01)00025-4 · PMID 11358690
29. Journal / agency Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, Nicolas JC, Cavaillès V, Balaguer P. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochemical Pharmacology. May 2006. doi:10.1016/j.bcp.2006.02.002 · PMID 16554039
30. Journal / agency Greene GL, Shiau AK, Nettles KW. New Molecular Mechanisms of Estrogen Action and Their Impact on Future Perspectives in Estrogen Therapy. Ernst Schering Research Foundation Workshop. 2004. doi:10.1007/978-3-662-05386-7_3 · PMID 15248503
31. Journal / agency Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Molecular Pharmacology. July 1998. doi:10.1124/mol.54.1.105 · PMID 9658195
32. Journal / agency Prossnitz ER, Arterburn JB. International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacological Reviews. July 2015. doi:10.1124/pr.114.009712 · PMID 26023144 · PMC4485017
33. Journal / agency Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstetrics and Gynecology International. 2013. doi:10.1155/2013/472720 · PMID 24379833 · PMC3863501
34. Journal / agency Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. European Journal of Obstetrics, Gynecology, and Reproductive Biology. July 1999. doi:10.1016/s0301-2115(98)00278-4 · PMID 10428318
35. Journal / agency Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. September 2000. doi:10.1093/ajhp/57.18.1669 · PMID 11006795
36. Journal / agency Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SR. Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res. July 2001. doi:10.1023/a:1010904815275 · PMID 11496940
37. Journal / agency Provinciali N, Suen C, Dunn BK, DeCensi A. Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Rev Clin Pharmacol. October 2016. doi:10.1080/17512433.2016.1231575 · PMID 27583816
38. Other Holland JF, Pollock RE. Holland-Frei Cancer Medicine 8. 2010
39. Journal / agency Blum A, Hathaway L, Mincemoyer R, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO. Hormonal, lipoprotein, and vascular effects of the selective estrogen receptor modulator raloxifene in hypercholesterolemic men. Am. J. Cardiol. 2000. doi:10.1016/s0002-9149(00)00802-x · PMID 10856400
40. Journal / agency Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J. Bone Miner. Res. 2001. doi:10.1359/jbmr.2001.16.11.2118 · PMID 11697809
41. Journal / agency Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur. J. Endocrinol. 2004. doi:10.1530/eje.0.1500481 · PMID 15080777
42. Journal / agency Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur. J. Endocrinol. 2004. doi:10.1530/eje.0.1500539 · PMID 15080785
43. Journal / agency Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2004. doi:10.1210/jc.2003-032058 · PMID 15292315
44. Journal / agency Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017. doi:10.1016/j.clgc.2016.08.026 · PMID 27771244
45. Journal / agency Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M, Akhondzadeh S. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Med Iran. 2015. PMID 26069170
46. Journal / agency Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, O'Donnell M, Galletly C, Liu D, Balzan R, Short B, Pellen D, Curtis J, Carr VJ, Kulkarni J, Schofield PR, Weickert CS. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol. Psychiatry. 2015. doi:10.1038/mp.2015.11 · PMID 25980345 · PMC4444978
47. Journal / agency Fujimura T, Takayama K, Takahashi S, Inoue S. Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine. Cancers. January 2018. doi:10.3390/cancers10020029 · PMID 29360794 · PMC5836061
48. Journal / agency Wang Q, Dong X, Wang Y, Li X. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2017. doi:10.1007/s00737-017-0773-2 · PMID 28849318
49. Journal / agency Carneiro AL, de Cassia de Maio Dardes R, Haidar MA. Estrogens plus raloxifene on endometrial safety and menopausal symptoms--semisystematic review. Menopause. July 2012. doi:10.1097/gme.0b013e31824a74ce · PMID 22549172
50. Journal / agency Nordt CA, DiVasta AD. Gynecomastia in adolescents. Current Opinion in Pediatrics. August 2008. doi:10.1097/MOP.0b013e328306a07c · PMID 18622190
51. Journal / agency Leung AK, Leung AA. Gynecomastia in Infants, Children, and Adolescents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2017. doi:10.2174/1872214811666170301124033 · PMID 28260521
52. Journal / agency Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. The Journal of Pediatrics. July 2004. doi:10.1016/j.jpeds.2004.03.057 · PMID 15238910
53. Journal / agency Kanakis GA, Nordkap L, Bang AK, Calogero AE, Bártfai G, Corona G, Forti G, Toppari J, Goulis DG, Jørgensen N. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. November 2019. doi:10.1111/andr.12636 · PMID 31099174
54. Journal / agency Sugiyama N, Barros RP, Warner M, Gustafsson JA. ERbeta: recent understanding of estrogen signaling. Trends in Endocrinology and Metabolism. September 2010. doi:10.1016/j.tem.2010.05.001 · PMID 20646931
55. Other Rare Diseases and Orphan Products: Accelerating Research and Development. 3 April 2011
56. Other Reducing Breast Cancer Risk with Drugs
57. Other Sydney Lou Bonnick. Bone Densitometry for Technologists. 10 November 2007
58. Other Li JJ, Johnson DS. Modern Drug Synthesis. 27 March 2013
59. Other J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
60. Other Index Nominum 2000: International Drug Directory. 2000
61. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 31 October 1999
62. Other Raloxifene Uses, Side Effects & Warnings
63. Journal / agency Thelancetoncology. A STARring role for raloxifene?. Lancet Oncol. 2006. doi:10.1016/S1470-2045(06)70701-X · PMID 16750489

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.